Patient demographics and baseline characteristics
| . | All patients, N = 60 . |
|---|---|
| Age, median (range), y | 63 (27-82) |
| ≥65 y, n (%) | 27 (45.0) |
| ≥75 y, n (%) | 6 (10.0) |
| Male, n (%) | 39 (65.0) |
| Race, n (%) | |
| White | 46 (76.7) |
| Black or African American | 2 (3.3) |
| Asian | 5 (8.3) |
| American Indian or Alaska Native | 1 (1.7) |
| Other | 1 (1.7) |
| Unknown/not reported | 5 (8.3) |
| Ethnicity, n (%) | |
| Hispanic/Latino | 6 (10.0) |
| Not Hispanic/Latino | 52 (86.7) |
| Not reported | 2 (3.3) |
| Geographic region, n (%) | |
| North America | 44 (73.3) |
| Europe | 12 (20.0) |
| Rest of world | 4 (6.7) |
| ECOG PS, n (%) | |
| 0 | 14 (23.3) |
| 1 | 46 (76.7) |
| Ann Arbor stage III/IV, n (%) | 44 (73.3) |
| IPI 3-5, n (%) | 35 (58.3) |
| Bulky disease (investigator assessment), n (%) | 24 (40.0) |
| Prior lines of therapy, median (range), n | 3 (2-9) |
| ≥3 prior lines, n (%) | 51 (85.0) |
| ≥4 prior lines, n (%) | 27 (45.0) |
| ≥5 prior lines, n (%) | 19 (31.7) |
| Cell of origin, n (%) | |
| GCB | 25 (41.7) |
| Non-GCB | 21 (35.0) |
| Unknown | 14 (23.3) |
| Site-reported cytogenetic status, n (%) | |
| HGBL with MYC and BCL2/BCL6 rearrangements | 16 (26.7) |
| NOS | 21 (35.0) |
| Missing | 23 (38.3) |
| Tumor burden, n (%) | |
| SPD low | 28 (46.7) |
| SPD high | 29 (48.3) |
| Missing | 3 (5.0) |
| HT score, n (%) | |
| 0-1 (HTlow) | 16 (26.7) |
| ≥2 (HThigh) | 28 (46.7) |
| Missing | 16 (26.7) |
| Prior CAR-T therapy, n (%) | |
| Axi-cel | 36 (60.0) |
| Tisa-cel | 10 (16.7) |
| Liso-cel | 6 (10.0) |
| Investigational CD19-directed CAR-Ts | 8 (13.3) |
| CAR-Ts as most recent line of therapy | 43 (71.7) |
| Best response to CAR-Ts, n (%) | |
| CR | 21 (35.0) |
| PR | 12 (20.0) |
| SD | 5 (8.3) |
| PD | 22 (36.7) |
| Time since prior CAR-T therapy, median, mo | 6.5 |
| Time to CAR-T relapse, n (%) | |
| ≤30 d | 4 (6.7) |
| ≤90 d | 29 (48.3) |
| ≤180 d | 40 (66.7) |
| R/R subgroup, n (%) | |
| Primary refractory to first-line therapy | 35 (58.3) |
| Refractory to most recent line of therapy | 46 (76.7) |
| Refractory to CAR-T therapy in any line | 43 (71.7) |
| . | All patients, N = 60 . |
|---|---|
| Age, median (range), y | 63 (27-82) |
| ≥65 y, n (%) | 27 (45.0) |
| ≥75 y, n (%) | 6 (10.0) |
| Male, n (%) | 39 (65.0) |
| Race, n (%) | |
| White | 46 (76.7) |
| Black or African American | 2 (3.3) |
| Asian | 5 (8.3) |
| American Indian or Alaska Native | 1 (1.7) |
| Other | 1 (1.7) |
| Unknown/not reported | 5 (8.3) |
| Ethnicity, n (%) | |
| Hispanic/Latino | 6 (10.0) |
| Not Hispanic/Latino | 52 (86.7) |
| Not reported | 2 (3.3) |
| Geographic region, n (%) | |
| North America | 44 (73.3) |
| Europe | 12 (20.0) |
| Rest of world | 4 (6.7) |
| ECOG PS, n (%) | |
| 0 | 14 (23.3) |
| 1 | 46 (76.7) |
| Ann Arbor stage III/IV, n (%) | 44 (73.3) |
| IPI 3-5, n (%) | 35 (58.3) |
| Bulky disease (investigator assessment), n (%) | 24 (40.0) |
| Prior lines of therapy, median (range), n | 3 (2-9) |
| ≥3 prior lines, n (%) | 51 (85.0) |
| ≥4 prior lines, n (%) | 27 (45.0) |
| ≥5 prior lines, n (%) | 19 (31.7) |
| Cell of origin, n (%) | |
| GCB | 25 (41.7) |
| Non-GCB | 21 (35.0) |
| Unknown | 14 (23.3) |
| Site-reported cytogenetic status, n (%) | |
| HGBL with MYC and BCL2/BCL6 rearrangements | 16 (26.7) |
| NOS | 21 (35.0) |
| Missing | 23 (38.3) |
| Tumor burden, n (%) | |
| SPD low | 28 (46.7) |
| SPD high | 29 (48.3) |
| Missing | 3 (5.0) |
| HT score, n (%) | |
| 0-1 (HTlow) | 16 (26.7) |
| ≥2 (HThigh) | 28 (46.7) |
| Missing | 16 (26.7) |
| Prior CAR-T therapy, n (%) | |
| Axi-cel | 36 (60.0) |
| Tisa-cel | 10 (16.7) |
| Liso-cel | 6 (10.0) |
| Investigational CD19-directed CAR-Ts | 8 (13.3) |
| CAR-Ts as most recent line of therapy | 43 (71.7) |
| Best response to CAR-Ts, n (%) | |
| CR | 21 (35.0) |
| PR | 12 (20.0) |
| SD | 5 (8.3) |
| PD | 22 (36.7) |
| Time since prior CAR-T therapy, median, mo | 6.5 |
| Time to CAR-T relapse, n (%) | |
| ≤30 d | 4 (6.7) |
| ≤90 d | 29 (48.3) |
| ≤180 d | 40 (66.7) |
| R/R subgroup, n (%) | |
| Primary refractory to first-line therapy | 35 (58.3) |
| Refractory to most recent line of therapy | 46 (76.7) |
| Refractory to CAR-T therapy in any line | 43 (71.7) |
Refractory was defined as disease progression during prior therapy or relapsed within 6 months from completion of any line of therapy. Relapse was defined as disease that recurred after a response lasting >6 months from completion of any line of therapy.
CD, cluster of differentiation; ECOG PS, Eastern Cooperative Oncology Group performance status; GCB, germinal center B cell; HGBL, high-grade B-cell lymphoma; HTlow, low HT score; IPI, International Prognostic Index; mo, months; NOS, not otherwise specified; SPD, sum of product diameter.